E. Ohman J or Asset Management AB Lowers Position in Boston Scientific Corporation $BSX

E. Ohman J or Asset Management AB lessened its stake in Boston Scientific Corporation (NYSE:BSX) by 4.1% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 397,419 shares of the medical equipment provider’s stock after selling 16,897 shares during the quarter. Boston Scientific makes up about 0.9% of E. Ohman J or Asset Management AB’s holdings, making the stock its 25th largest position. E. Ohman J or Asset Management AB’s holdings in Boston Scientific were worth $38,800,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Steph & Co. bought a new position in Boston Scientific during the 3rd quarter valued at $25,000. 1248 Management LLC bought a new stake in shares of Boston Scientific in the 1st quarter worth $26,000. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific in the second quarter valued at about $26,000. Sound Income Strategies LLC lifted its position in shares of Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares in the last quarter. Finally, Kilter Group LLC purchased a new position in Boston Scientific during the second quarter worth about $30,000. Institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on BSX shares. Needham & Company LLC reiterated a “buy” rating and issued a $121.00 price objective on shares of Boston Scientific in a research note on Friday, October 17th. Canaccord Genuity Group reduced their target price on Boston Scientific from $132.00 to $131.00 and set a “buy” rating for the company in a report on Wednesday, December 17th. Truist Financial decreased their price target on Boston Scientific from $130.00 to $120.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Wells Fargo & Company boosted their price objective on Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Finally, Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $118.00 to $125.00 in a research note on Monday, September 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $124.85.

Boston Scientific Price Performance

Boston Scientific stock opened at $96.02 on Friday. The business’s 50 day simple moving average is $98.53 and its 200 day simple moving average is $101.08. Boston Scientific Corporation has a 12 month low of $85.98 and a 12 month high of $109.50. The company has a market cap of $142.35 billion, a price-to-earnings ratio of 51.35, a PEG ratio of 1.93 and a beta of 0.67. The company has a current ratio of 1.51, a quick ratio of 0.96 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.71 by $0.04. The firm had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business’s revenue was up 20.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Sell-side analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director directly owned 24,134 shares in the company, valued at approximately $2,371,889.52. This trade represents a 34.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 143,095 shares of company stock valued at $14,228,950 over the last three months. 0.50% of the stock is currently owned by insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.